Disease · MONDO_0005399

venous thromboembolism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. venous thromboembolism. Diseases, record MONDO_0005399. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005399

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: venous thromboembolism; Open Targets
Open Targets ID: MONDO_0005399; Open Targets
Other names: VTE; Open Targets
MeSH: D054556; MeSH
NCI Thesaurus: C99537; NCI Thesaurus
Highest stage of its drugs: Approval, for 10 of its 33 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs33

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIVAROXABAN	CHEMBL198362	Small molecule	Approval	EMA Human Drugs and PMDA	38	33	31	Drugs and targets
APIXABAN	CHEMBL231779	Small molecule	Approval	EMA Human Drugs	31	29	26	Drugs and targets
DALTEPARIN SODIUM	CHEMBL1201460	Oligosaccharide	Approval	DailyMed	17	16	11	Drugs and targets
EDOXABAN	CHEMBL1269025	Small molecule	Approval	EMA Human Drugs and PMDA	15	12	12	Drugs and targets
DABIGATRAN ETEXILATE	CHEMBL539697	Small molecule	Approval	EMA Human Drugs	13	8	8	Drugs and targets
ENOXAPARIN SODIUM	CHEMBL1201476	Oligosaccharide	Approval	EMA Human Drugs and PMDA	11	8	2	Drugs and targets
BETRIXABAN	CHEMBL512351	Small molecule	Approval	FDA and TTD	4	1	1	Drugs and targets
FONDAPARINUX SODIUM	CHEMBL1200644	Oligosaccharide	Approval	PMDA	2	1	1	Drugs and targets
EDOXABAN TOSYLATE	CHEMBL2105682	Small molecule	Approval	TTD	1	0	0	Drugs and targets
PROTEIN C CONCENTRATE (HUMAN)	CHEMBL5315087		Approval	PMDA	1	0	0	Drugs and targets

1 to 10 of 33

See all 33 drugs

Targets26

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SERPINC1	Antithrombin-III	9	Antithrombin-III activator	Approval	https://conductscience.org/library/genes/462	Drugs and targets
F10	Coagulation factor X	6	Coagulation factor X inhibitor	Approval	https://conductscience.org/library/genes/2159	Drugs and targets
F2	Prothrombin	2	Thrombin inhibitor	Approval	https://conductscience.org/library/genes/2147	Drugs and targets
VKORC1	Vitamin K epoxide reductase complex subunit 1	2	Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor	Phase 3	https://conductscience.org/library/genes/79001	Drugs and targets
F11	Coagulation factor XI	1	Coagulation factor XI inhibitor	Phase 3	https://conductscience.org/library/genes/2160	Drugs and targets
F8	Coagulation factor VIII	1	Coagulation factor VIII inhibitor	Phase 2	https://conductscience.org/library/genes/2157	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets
IL11RA	Interleukin-11 receptor subunit alpha	1	Interleukin 11 receptor alpha agonist	Unknown	https://conductscience.org/library/genes/3590	Drugs and targets
PGR	Progesterone receptor	1	Progesterone receptor agonist	Unknown	https://conductscience.org/library/genes/5241	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5422	Drugs and targets

1 to 10 of 26

See all 26 targets

Trials98

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05022563	Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea		55,759	2023-08-03	Venous Thromboembolism	APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN, WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT05795062	Treatment Patterns Among Patients With Venous Thromboembolism in the United States		13,945	2024-11-22	Venous Thromboembolism	APIXABAN, WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT02943993	Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe		2,809	2022-05-02	Venous Thromboembolism	EDOXABAN	Its record names the disease	ClinicalTrials.gov
NCT00680186	Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)	Phase 3	2,589	2012-06-14	Thromboembolism	DABIGATRAN ETEXILATE, WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT00291330	Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism	Phase 3	2,564	2011-02-11	Thromboembolism	DABIGATRAN ETEXILATE, WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT03045406	Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer	Phase 3	1,170	2025-06-18	Venous Thromboembolism	APIXABAN	Its record names the disease	ClinicalTrials.gov
NCT02073682	Cancer Venous Thromboembolism (VTE)	Phase 3	1,046	2018-10-24	Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer	EDOXABAN, HEPARIN	Its record names the disease	ClinicalTrials.gov
NCT02234843	EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis	Phase 3	500	2020-04-01	Venous Thromboembolism	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT04362085	Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care	Phase 3	465	2025-01-30	COVID-19	DALTEPARIN SODIUM, ENOXAPARIN, ENOXAPARIN SODIUM, HEPARIN, TINZAPARIN	Its record names the disease	ClinicalTrials.gov
NCT00942968	Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer	Phase 4	338	2017-02-24	Cancer	DALTEPARIN SODIUM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 98

See all 98 trials

Comparisons in its trials83

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Apixaban vs Warfarin: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital	11,966 of 11,966	1,979 of 1,979	13,945	NCT05795062	Trial comparisons
Dabigatran 150 mg vs Warfarin: serious adverse events	156 of 1,280	153 of 1,288	2,568	NCT00680186	Trial comparisons
Dabigatran 150 mg vs Warfarin: serious adverse events	165 of 1,273	150 of 1,266	2,539	NCT00291330	Trial comparisons
Apixaban vs Dalteparin: Recurrent Venous Thromboembolism	32 of 576	46 of 579	1,155	NCT03045406	Trial comparisons
Apixaban vs Dalteparin: deaths from any cause	135 of 576	153 of 579	1,155	NCT03045406	Trial comparisons
Apixaban vs Dalteparin: serious adverse events	255 of 576	276 of 579	1,155	NCT03045406	Trial comparisons
Edoxaban Group vs Dalteparin Group: Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event	67 of 522	71 of 524	1,046	NCT02073682	Trial comparisons
Edoxaban Group vs Dalteparin Group: Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death	235 of 522	228 of 524	1,046	NCT02073682	Trial comparisons
Edoxaban Group vs Dalteparin Group: Number of Participants With Adjudicated Major Bleeding Events While on Treatment	32 of 522	16 of 524	1,046	NCT02073682	Trial comparisons
Edoxaban Group vs Dalteparin Group: Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period	41 of 522	59 of 524	1,046	NCT02073682	Trial comparisons

1 to 10 of 83

See all 83 comparisons in its trials

Papers from its trials139

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34877446	RESULT	1	PubMed
34078109	RESULT	1	PubMed
33709339	RESULT	1	PubMed
33247808	RESULT	1	PubMed
33073581	RESULT	1	PubMed
33007077	RESULT	1	PubMed
32992075	RESULT	1	PubMed
32538234	RESULT	1	PubMed
32000266	RESULT	1	PubMed
31630479	RESULT	2	PubMed

1 to 10 of 139

See all 139 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005399

GET https://conductscience.org/api/diseases/v1/MONDO_0005399/drugs?page=2

API reference For AI assistants